Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<ns4:p><ns4:bold>Background</ns4:bold><ns4:bold>.</ns4:bold> Few hospitals in high malaria endemic countries in Africa have the diagnostic capacity for clinically distinguishing acute bacterial meningitis (ABM) from cerebral malaria (CM). As a result, empirical use of antibiotics is necessary. A biochemical marker of ABM would facilitate precise clinical diagnosis and management of these infections and enable rational use of antibiotics.</ns4:p><ns4:p> <ns4:bold>Methods.</ns4:bold> We used label-free protein quantification by mass spectrometry to identify cerebrospinal fluid (CSF) markers that distinguish ABM (n=37) from CM (n=22) in Kenyan children. Fold change (FC) and false discovery rates (FDR) were used to identify differentially expressed proteins. Subsequently, potential biomarkers were assessed for their ability to discriminate between ABM and CM using receiver operating characteristic (ROC) curves.</ns4:p><ns4:p> <ns4:bold>Results.</ns4:bold> The host CSF proteome response to ABM (<ns4:italic>Haemophilus</ns4:italic> <ns4:italic>influenza</ns4:italic> and <ns4:italic>Streptococcus</ns4:italic> <ns4:italic>pneumoniae</ns4:italic>) is significantly different to CM. Fifty two proteins were differentially expressed (FDR&lt;0.01, Log FC≥2), of which 83% (43/52) were upregulated in ABM compared to CM. Myeloperoxidase and lactotransferrin were present in 37 (100%) and 36 (97%) of ABM cases, respectively, but absent in CM (n=22). Area under the ROC curve (AUC), sensitivity, and specificity were assessed for myeloperoxidase (1, 1, and 1; 95% CI, 1-1) and lactotransferrin (0.98, 0.97, and 1; 95% CI, 0.96-1).</ns4:p><ns4:p> <ns4:bold>Conclusion.</ns4:bold> Myeloperoxidase and lactotransferrin have a high potential to distinguish ABM from CM and thereby improve clinical management. Their validation requires a larger cohort of samples that includes other bacterial aetiologies of ABM.</ns4:p>

Original publication

DOI

10.12688/wellcomeopenres.11958.1

Type

Journal

Wellcome Open Research

Publisher

F1000 Research Ltd

Publication Date

03/07/2017

Volume

2

Pages

47 - 47